Galit Elad‐Sfadia

1.6k total citations
23 papers, 1.3k citations indexed

About

Galit Elad‐Sfadia is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Galit Elad‐Sfadia has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Immunology. Recurrent topics in Galit Elad‐Sfadia's work include Protein Kinase Regulation and GTPase Signaling (6 papers), Galectins and Cancer Biology (5 papers) and Protein Tyrosine Phosphatases (5 papers). Galit Elad‐Sfadia is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (6 papers), Galectins and Cancer Biology (5 papers) and Protein Tyrosine Phosphatases (5 papers). Galit Elad‐Sfadia collaborates with scholars based in Israel, United States and Russia. Galit Elad‐Sfadia's co-authors include Roni Haklai, Yoel Kloog, Yoel Kloog, Ariella Paz, Hans‐Joachim Gabius, Ronit Haklai, Yaakov Egozi, Adi Zundelevich, Fanny Reichert and Shlomo Rotshenker and has published in prestigious journals such as Journal of Biological Chemistry, Nano Letters and PLoS ONE.

In The Last Decade

Galit Elad‐Sfadia

22 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Galit Elad‐Sfadia Israel 15 899 589 271 134 102 23 1.3k
Brian Koss United States 14 912 1.0× 399 0.7× 449 1.7× 83 0.6× 128 1.3× 26 1.3k
Yong-Qing Zhou China 22 537 0.6× 322 0.5× 287 1.1× 107 0.8× 107 1.0× 33 1.2k
Roni Haklai Israel 21 1.4k 1.6× 605 1.0× 472 1.7× 247 1.8× 162 1.6× 37 1.9k
Jason Hatakeyama United States 13 678 0.8× 702 1.2× 390 1.4× 101 0.8× 176 1.7× 17 1.3k
Christophe Schneider France 19 617 0.7× 307 0.5× 307 1.1× 131 1.0× 242 2.4× 41 1.1k
Mélanie Tichet France 16 674 0.7× 303 0.5× 441 1.6× 103 0.8× 196 1.9× 20 1.1k
Marina Kochetkova Australia 19 534 0.6× 331 0.6× 595 2.2× 129 1.0× 203 2.0× 26 1.1k
Jacqueline Lesperance United States 16 819 0.9× 248 0.4× 478 1.8× 143 1.1× 205 2.0× 25 1.2k
Damon B. Bowe United States 10 716 0.8× 247 0.4× 257 0.9× 148 1.1× 109 1.1× 11 949
Georgia Mavria United Kingdom 16 780 0.9× 196 0.3× 238 0.9× 275 2.1× 187 1.8× 29 1.2k

Countries citing papers authored by Galit Elad‐Sfadia

Since Specialization
Citations

This map shows the geographic impact of Galit Elad‐Sfadia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galit Elad‐Sfadia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galit Elad‐Sfadia more than expected).

Fields of papers citing papers by Galit Elad‐Sfadia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galit Elad‐Sfadia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galit Elad‐Sfadia. The network helps show where Galit Elad‐Sfadia may publish in the future.

Co-authorship network of co-authors of Galit Elad‐Sfadia

This figure shows the co-authorship network connecting the top 25 collaborators of Galit Elad‐Sfadia. A scholar is included among the top collaborators of Galit Elad‐Sfadia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galit Elad‐Sfadia. Galit Elad‐Sfadia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
McDonnell, Cormac, Oleksii O. Peltek, Mariam Amer, et al.. (2024). In-Brain Multiphoton Imaging of Vaterite Cargoes Loaded with Carbon Dots. Nano Letters. 24(27). 8232–8239. 13 indexed citations
4.
Marcu‐Malina, Victoria, Einav Vax, Jasmine Jacob‐Hirsch, et al.. (2017). Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. Frontiers in Immunology. 8. 799–799. 22 indexed citations
5.
Yaniv, Isaac, Shifra Ash, Ian J. Cohen, et al.. (2015). The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. Oncotarget. 6(32). 33834–33848. 30 indexed citations
6.
Abramovitch, Shirley, et al.. (2014). Vitamin D and S-Farnesylthiosalicylic Acid Have a Synergistic Effect on Hepatic Stellate Cells Proliferation. Digestive Diseases and Sciences. 59(10). 2462–2469. 15 indexed citations
7.
Kloog, Yoel, Galit Elad‐Sfadia, Roni Haklai, & Adam Mor. (2013). Ras Chaperones. ˜The œEnzymes. 33 Pt A. 267–289. 8 indexed citations
8.
Rak, Roni, Galit Elad‐Sfadia, Roni Haklai, et al.. (2012). Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton. Oncotarget. 3(6). 629–639. 37 indexed citations
9.
Oron, Tal, Galit Elad‐Sfadia, Roni Haklai, et al.. (2011). Prevention of Induced Colitis in Mice by the Ras Antagonist Farnesylthiosalicylic Acid. Digestive Diseases and Sciences. 57(2). 320–326. 10 indexed citations
10.
Nevo, Yoram, Shlomit Aga‐Mizrachi, Galit Elad‐Sfadia, et al.. (2011). The Ras Antagonist, Farnesylthiosalicylic Acid (FTS), Decreases Fibrosis and Improves Muscle Strength in dy2J/dy2J Mouse Model of Muscular Dystrophy. PLoS ONE. 6(3). e18049–e18049. 20 indexed citations
11.
Haklai, Roni, Galit Elad‐Sfadia, Elsa M. Reyes‐Reyes, et al.. (2011). Oncogenic Synergism between ErbB1, Nucleolin, and Mutant Ras. Cancer Research. 71(6). 2140–2151. 58 indexed citations
13.
Haklai, Roni, Galit Elad‐Sfadia, Yaakov Egozi, & Yoel Kloog. (2007). Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemotherapy and Pharmacology. 61(1). 89–96. 62 indexed citations
14.
Beiner, Mario, Hagit Niv, Ronit Haklai, et al.. (2006). Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. International Journal of Gynecological Cancer. 16(S1). 200–206. 11 indexed citations
15.
Ashery, Uri, Ofer Yizhar, Barak Rotblat, et al.. (2006). Spatiotemporal Organization of Ras Signaling: Rasosomes and the Galectin Switch. Cellular and Molecular Neurobiology. 26(4-6). 469–493. 61 indexed citations
16.
Beiner, Mario, Hagit Niv, Ronit Haklai, et al.. (2006). Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. International Journal of Gynecological Cancer. 16. 200–206. 3 indexed citations
17.
Elad‐Sfadia, Galit, et al.. (2004). Galectin-3 Augments K-Ras Activation and Triggers a Ras Signal That Attenuates ERK but Not Phosphoinositide 3-Kinase Activity. Journal of Biological Chemistry. 279(33). 34922–34930. 242 indexed citations
18.
George, Jacob, Jessica Sack, Iris Barshack, et al.. (2003). Inhibition of Intimal Thickening in the Rat Carotid Artery Injury Model by a Nontoxic Ras Inhibitor. Arteriosclerosis Thrombosis and Vascular Biology. 24(2). 363–368. 20 indexed citations
19.
Elad‐Sfadia, Galit, et al.. (2002). Galectin-1 Augments Ras Activation and Diverts Ras Signals to Raf-1 at the Expense of Phosphoinositide 3-Kinase. Journal of Biological Chemistry. 277(40). 37169–37175. 184 indexed citations
20.
Paz, Ariella, et al.. (2001). Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene. 20(51). 7486–7493. 327 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026